Real-World Safety of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Comparative Cohort Studies.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
188 patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[RESULTS] Twenty retrospective cohort studies were included, all using electronic health record data.
[INTRODUCTION] Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in small cell lung cancer (SCLC).
- 연구 설계 systematic review
APA
Koo J, Yiu CH, et al. (2026). Real-World Safety of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Comparative Cohort Studies.. Current oncology reports, 28(1). https://doi.org/10.1007/s11912-026-01774-7
MLA
Koo J, et al.. "Real-World Safety of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Comparative Cohort Studies.." Current oncology reports, vol. 28, no. 1, 2026.
PMID
41886234 ↗
Abstract 한글 요약
[INTRODUCTION] Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in small cell lung cancer (SCLC). However, ICIs can cause treatment-related adverse events (TRAEs), particularly immune-related adverse events (irAEs), which may compromise treatment efficacy and patient quality of life. Most ICI safety data is derived from clinical trials, which may not reflect real-world populations. This systematic review evaluated the real-world safety of ICIs compared to other therapies in SCLC.
[METHODS] A systematic search of MEDLINE, Embase, Scopus, CINAHL was conducted from inception to July 21, 2025. Eligible studies were observational cohort studies reporting safety outcomes for ICIs versus other cancer therapies (e.g., chemotherapy, targeted therapy) in SCLC. Study quality was assessed using the Newcastle-Ottawa Scale. A narrative synthesis was conducted to summarise key findings.
[RESULTS] Twenty retrospective cohort studies were included, all using electronic health record data. Cohort sizes ranged from 14 to 188 patients. Nineteen studies were rated as poor quality due to inadequate adjustment for confounding variables. Across studies, TRAE incidence was comparable between ICI plus chemotherapy combination and chemotherapy alone. Similarly, TRAE and irAE rates were consistent across different ICI plus chemotherapy regimens. Evidence comparing ICIs to targeted therapy was limited.
[CONCLUSION] Real-world evidence suggests that adding ICIs to chemotherapy does not substantially increase toxicity in patients with SCLC, and safety profiles are generally consistent across ICI regimens. However, findings are constrained by small sample sizes and poor methodological quality. High-quality, large-scale observational studies are needed to validate these results and better inform clinical decision-making.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s11912-026-01774-7.
[METHODS] A systematic search of MEDLINE, Embase, Scopus, CINAHL was conducted from inception to July 21, 2025. Eligible studies were observational cohort studies reporting safety outcomes for ICIs versus other cancer therapies (e.g., chemotherapy, targeted therapy) in SCLC. Study quality was assessed using the Newcastle-Ottawa Scale. A narrative synthesis was conducted to summarise key findings.
[RESULTS] Twenty retrospective cohort studies were included, all using electronic health record data. Cohort sizes ranged from 14 to 188 patients. Nineteen studies were rated as poor quality due to inadequate adjustment for confounding variables. Across studies, TRAE incidence was comparable between ICI plus chemotherapy combination and chemotherapy alone. Similarly, TRAE and irAE rates were consistent across different ICI plus chemotherapy regimens. Evidence comparing ICIs to targeted therapy was limited.
[CONCLUSION] Real-world evidence suggests that adding ICIs to chemotherapy does not substantially increase toxicity in patients with SCLC, and safety profiles are generally consistent across ICI regimens. However, findings are constrained by small sample sizes and poor methodological quality. High-quality, large-scale observational studies are needed to validate these results and better inform clinical decision-making.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s11912-026-01774-7.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response.
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.